Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: ...
We recently compiled a list of the 7 Most Promising Gene Editing Stocks According to Analysts. Wave Life Sciences Ltd. tops ...
TipRanks on MSN
Sirnaomics completes phase I trial of cancer drug STP707 and files clinical report with FDA
Sirnaomics Ltd. ( ($HK:2257) ) has issued an announcement. Sirnaomics Ltd. has announced that its subsidiary Sirnaomics, Inc. has completed a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback